Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

tments pledged to a bank as collateral for two letters of credit; the first in the amount of $6,000,000 was issued in connection with the potentially refundable upfront payment received under the collaboration agreement with Centocor and the second in the amount of CDN$640,000 was granted in favour of a landlord in relation to the lease of a building. As at December 31, 2007, restricted cash is composed of third-party Asset-Backed Commercial Paper (ABCP). These investments were due to mature during the second quarter of 2007 but, as a result of a disruption in the credit markets, particularly in the ABCP market, they did not settle on maturity and currently remain outstanding. At the time these investments were acquired, the ABCP were rated R1-high by Dominion Bond Rating Service, which is the highest credit rating for this type of investment. The ABCP are currently subject to a restructuring proposal under a standstill agreement which is expected to result in the conversion of the ABCP into longer-term financial instruments with maturities corresponding to the underlying assets. A Pan-Canadian Investors Committee (the Committee) was established to oversee the orderly restructuring of these instruments during this standstill period. A restructuring plan was announced by the Committee on December 23, 2007, and is anticipated to be completed by the end of March, 2008. During the quarter ended December 31, 2007, the Company recorded a provision for losses in the amount of $1,184,000 in respect of ABCP, reflecting the Company's estimated reduction in the fair value of these investments as at December 31, 2007. The Company estimated the fair value of the ABCP using a probability weighted discounted cash flow approach, based on its best estimates of the time period over which the assets are going to generate cash flows ranging from 7 to 30 years based on the proposed restructuring, the coupon interest rate, the discount rate to apply to the net cash flows anticipated to b
'/>"/>
SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 The family ... bleeding has filed a Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... thinner, Bernstein Liebhard LLP reports. According to the complaint, ... District of Vermont on July 25th, the decedent had ... suffered an irreversible brain bleed that ultimately led to ...
(Date:7/30/2014)... Hawley, Pennsylvania (PRWEB) July 30, 2014 ... and have contributed over $8,500 to ensure its protection. ... Resort, presents a check to the Delaware Highlands Conservancy ... Partnership program. The small $2-per-stay donations add up fast, ... future of the Upper Delaware River Region. , The ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- Some obese people ... the reward centers in their brains when they see ... how this mutation triggers feelings of pleasure and gratification ... help improve strategies designed to prevent overeating, the scientists ... obese. Obesity is typically caused by a combination ...
(Date:7/30/2014)... KY (PRWEB) July 30, 2014 DRE ... pleased to announce the launch of its Medical ... online resource for medical professionals and equipment vendors. , ... shows and conventions in the United States and around ... the calendar, and that number is always growing. , ...
(Date:7/30/2014)... ... ... ... , UCLA researchers interviewed people ... published this week in the peer-reviewed journal Quality of Life Research , a UCLA team led by Dr. Brennan Spiegel interviewed ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Gene Mutation May Make Food More Tempting 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 2Health News:Diverticulitis patients reveal psychological, physical symptoms long after acute attacks 3
... Increased 74.0% to $59.0 Million in 2Q08 -- ... Increased 43.4% to $13.9 Million -- ... EPS $0.15 --, NEW YORK, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- ... dedicated to,improving health through the development, manufacture and commercialization,of a ...
... of $17.9 Million Treatment Tip and Other Consumables Revenue Up ... ... Thermage, Inc.,(Nasdaq: THRM ), a leader in non-invasive tissue tightening ... ended,June 30, 2008., Revenue for the second quarter of 2008 totaled ...
... may provide context for tumor formation, new treatments ... more about normal cells that give rise to cancer ... according to Duke University Medical Center researchers who identified ... "Identifying the specific, normal cells that cancer come from ...
... more common, study finds , , MONDAY, Aug. 11 ... adults don,t have the 20/20 vision physicians consider ... an irregular corneal curve known as astigmatism, a ... that such common eye-focus problems -- collectively known ...
... fewer disabilities, study finds , , MONDAY, Aug. 11 (HealthDay News) ... -- and even the creeping ravages of time -- at ... found that older runners live longer and suffer fewer disabilities ... to a variety of aerobic exercises, including walking, said the ...
... (August 11, 2008) Scientists from the University of ... people who develop Alzheimer,s disease may show signs of ... educational achievement. Their research appears online this month in ... , Participants in the Nun Study were studied to ...
Cached Medicine News:Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 2Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 3Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 4Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 5Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 6Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 7Health News:American Oriental Bioengineering Reports Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 2Health News:Thermage Announces Second Quarter 2008 Financial Results 3Health News:Thermage Announces Second Quarter 2008 Financial Results 4Health News:Thermage Announces Second Quarter 2008 Financial Results 5Health News:Thermage Announces Second Quarter 2008 Financial Results 6Health News:Thermage Announces Second Quarter 2008 Financial Results 7Health News:Thermage Announces Second Quarter 2008 Financial Results 8Health News:Thermage Announces Second Quarter 2008 Financial Results 9Health News:Researchers Hunt Normal Cells That Give Rise to Cancer 2Health News:Half of U.S. Adults Lack 20/20 Vision 2Health News:Half of U.S. Adults Lack 20/20 Vision 3Health News:Run for Your Life 2Health News:Run for Your Life 3Health News:Signs of Alzheimer's disease may be present decades before diagnosis 2
(Date:7/30/2014)... WESTFORD, Mass. , July 30, 2014 ... in laser- and light-based aesthetic treatments for non-invasive and minimally ... promoted Executive Vice President, Chief Operating Officer and Chief Financial ... Company, effective August 1, 2014.  Baker, 53, will continue to ... from Michael Davin , who remains Chairman and Chief ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... Jude scientists, findings in ataxia telangiectasia-like disease ... the links between brain disease and cancer ... Jan. 14 Scientists at ... apart the biological details distinguishing two related ...
... VALENCIA, Calif., Jan. 13 MannKind Corporation ... of its trial to demonstrate equivalence of its commercial ... used in clinical trials to deliver AFRESA(TM), MannKind,s ultra ... trials. Study 138 - Bioequivalence of Clinical and ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3MannKind Reports Successful Completion of Device Bioequivalence Trial 2MannKind Reports Successful Completion of Device Bioequivalence Trial 3
The autoclavable, aluminum needle box is designed to store loaded needles and help protect personnel from exposure. Each shield consists of an aluminum box with faceplate to match the grid pattern th...
... The TheraSeed® Pd-103 implant is a combination ... remarkable visibility that makes TheraSeed® treatment an ... can be confident that every TheraSeed® implant ... services which is required by clinicians who ...
... Bard BrachyStar® Needle is designed to help ... and clinically effective brachytherapy procedure. All needles ... tips and polished surfaces for smooth entry ... configurations and sizes assures an ideal match ...
... is designed to help you achieve one ... brachytherapy procedure. All needles are engineered for ... surfaces for smooth entry and exit. A ... assures an ideal match with procedural needs ...
Medicine Products: